# US 2021/0277458 A1 · Methods, systems, and aparatus for nucleic acid detection

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0277458 A1
- Document ID: US20210277458A1
- Status: Published application
- Kind: A1
- Application number: 16/839,057
- Filed: 2020-04-02
- Published: 2021-09-09
- Earliest claimed: 2019-04-02
- Assignees: Mission Bio, Inc.
- Applicants: Mission Bio, Inc.
- Inventors: Dalia Dhingra; David Ruff; Pedro Mendez; Aik Ooi
- Web page: https://patentgrep.com/patent/US20210277458A1

## CPC

- C12N 15/1075: {by coupling phenotype to genotype, not provided for in other groups of this subclass}
- C12Q 1/6853: using modified primers or templates
- C12N 15/62: DNA sequences coding for fusion proteins
- C12Q 1/6806: Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay (C12Q1/6804 takes precedence)
- C12Q 1/6869: Methods for sequencing
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- C12Q 2600/156: Polymorphic or mutational markers
- C12Q 2600/158: Expression markers
- C12Q 2600/16: Primer sets for multiplex assays
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

Provided herein are methods for detection and characterization of a target nucleic acid from a single cell. One embodiment is a method for detection of a BCR-ABL gene fusion in a nucleic acid sample from a single cell having or suspected of having a BCR-ABL fusion transcript. One preferred implementation of the invention includes providing a nucleic acid amplification primer set complementary to a target nucleic acid suspected of having a BCR-ABL fusion transcript. In some embodiments, one or both primers of the nucleic acid amplification primer set have a barcode identification sequence. Also provided are methods for the detection of an AML tumor, methods are used for the detection of a leukemia, for the detection of a myeloid leukemia, and to determine the prognosis of a patient suspected of having a BCR-ABL fusion transcript.

## Claims

### Claim 1

A method for detection of gene expression in a nucleic acid sample from a single cell, the method comprising:
selecting one or more target nucleic acid sequence in an individual cell, where the target nucleic acid sequence is contained in a DNA or RNA; providing a sample having one or more individual single cell;
encapsulating an individual cell in a drop;
incubating the encapsulated cell protease in the drop to produce a cell lysate;
providing a nucleic acid amplification primer set complementary to a target nucleic acid, where at least one primer of the nucleic acid amplification primer set comprises a barcode identification sequence;
performing a reverse transcription and nucleic acid amplification reaction to form an amplification product from the nucleic acid of a single cell; and
determining whether the target nucleic acid is expressed if the target nucleic acid comprises a transcript.

### Claim 2 (depends on 1)

A method according to claim 1, further comprising:
providing an affinity reagent that comprises a nucleic acid sequence complementary to a barcode sequence of one of more nucleic acid primer, where the affinity reagent comprising said nucleic acid sequence complementary to the barcode sequence is capable of binding to a nucleic acid amplification primer comprising a barcode sequence; and
contacting an affinity reagent to the amplification product comprising amplicons under conditions sufficient for binding of the affinity reagent to the target nucleic acid to form an affinity reagent bound target nucleic acid.

### Claim 3 (depends on 1)

A method according to claim 1, further comprising nucleic acid sequencing of an amplification product or amplicon to determine whether the target nucleic acid is present.

### Claim 4 (depends on 1)

A method according to claim 1, further comprising nucleic acid sequencing of an amplification product or amplicon to determine the target nucleic acid level relative to other targeted nucleic acids.

### Claim 5 (depends on 1)

A method according to claim 1, further comprising nucleic acid sequencing of an amplification product or amplicon to determine whether the target nucleic acid comprises a fusion transcript.

### Claim 6 (depends on 1)

A method according to claim 1, further comprising nucleic acid sequencing of an amplification product or amplicon to determine whether the target nucleic acid comprises a BCR-ABL1 fusion transcript.

### Claim 7 (depends on 1)

A method according to claim 1, wherein the nucleic acid amplification primer set spans a splice junction.

### Claim 8 (depends on 1)

A method according to claim 1, wherein the nucleic acid amplification primer set spans a BCR-ABL splice junction.

### Claim 9 (depends on 1)

A method according to claim 1, comprising a forward amplification primer having an embedded barcode identification sequence.

### Claim 10 (depends on 1)

A method according to claim 1, comprising a reverse amplification primer having an embedded barcode identification sequence.

### Claim 11 (depends on 1)

A method according to claim 1, wherein the method is used for the detection of an AML tumor.

### Claim 12 (depends on 1)

A method according to claim 1, wherein the method is used for the detection of a leukemia.

### Claim 13 (depends on 1)

A method according to claim 1, wherein the method is used for the detection of a myeloid leukemia.

### Claim 14 (depends on 1)

A method according to claim 1, wherein the method is used to determine the prognosis of a patient suspected of having a BCR-ABL fusion transcript.

### Claim 15 (depends on 1)

A method according to claim 1, wherein the nucleic acid amplification primer set comprises the sequence ACTCCAGACTGTCCACAGCA (SEQ ID NO: 1) or a variant thereof with one to three nucleotide substitutions or deletions at either end is used as a forward primer for amplification, and the sequence TTGGGGTCATTTTCACTGGGTCCAGCGAGAAGGT (SEQ ID NO: 2) or a variant thereof with one to four nucleotide substitutions or deletions at either end is used as a reverse primer for amplification.

### Claim 16 (depends on 1)

A method according to claim 1, wherein an individual cell is encapsulated in a single drop comprising a reaction mixture in an aqueous, an aqueous emulsion in oil, or an aqueous suspension in oil.

### Claim 17 (depends on 17)

A method according to claim 17, wherein the reaction mixture comprises proteinase K or another cytolytic protease.

### Claim 18 (depends on 18)

A method according to claim 18, wherein the cytolytic protease is heat inactivated before or during the nucleic acid amplification reaction.

### Claim 19 (depends on 1)

A method according to claim 1, wherein the nucleic acid amplification reaction is the polymerase chain reaction or a known variant thereof.

### Claim 20

A BCR-ABL gene fusion.
